Compare LGVN & NTWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGVN | NTWK |
|---|---|---|
| Founded | 2014 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0M | 39.7M |
| IPO Year | 2021 | 1997 |
| Metric | LGVN | NTWK |
|---|---|---|
| Price | $0.80 | $4.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 379.1K | 56.7K |
| Earning Date | 05-08-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 50.76 | ★ 316.67 |
| EPS | N/A | ★ N/A |
| Revenue | $709,000.00 | ★ $73,088,687.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.81 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 13.40 |
| 52 Week Low | $0.48 | $2.73 |
| 52 Week High | $1.80 | $5.75 |
| Indicator | LGVN | NTWK |
|---|---|---|
| Relative Strength Index (RSI) | 49.34 | 67.24 |
| Support Level | $0.74 | $4.55 |
| Resistance Level | $0.86 | $4.90 |
| Average True Range (ATR) | 0.07 | 0.22 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 78.25 | 76.54 |
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
NETSOL Technologies Inc is an information technology and enterprise software solutions provider to original equipment manufacturers (OEMs), dealerships, and financial institutions to sell, finance, and lease assets. The firm's products include Transcend Retail, Transcend Finance, Transcend Marketplace, Transcend Consultancy, and Transcend AI Labs, catering to its customers in the different stages of how assets are sold, financed, and leased. Its primary sources of revenue are licensing, subscriptions, modification, enhancement, and support of its suite of financial applications offered to businesses in the finance and leasing space, as well as automotive digital retail. The company has three reportable segments: Asia-Pacific, its key revenue-generating market, North America, and Europe.